Highlight
This study demonstrates that tissue-free circulating tumor DNA (ctDNA) assays, which do not require sequencing primary tumor tissue, can robustly detect molecular residual disease (MRD) in early triple negative breast cancer (TNBC). Such assays show strong prognostic value for recurrence, comparable lead times to tumor-informed assays, and potential to simplify clinical workflows.
